Jianjun Xi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jianjun Xi has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Yu Cao
Department of Pharmaceutical Preparation, Hangzhou Xixi Hospital, Hangzhou, 310023, Zhejiang Province, China
4 shared publicationsLiping Fu
Department of Pharmacy, Shaoxing TCM Hospital Affiliated to Zhejiang Chinese Medical University, Shaoxing, 312000, Zhejiang Province, China
3 shared publicationsQiao Tong
Department of Pharmaceutical Preparation Hangzhou Xixi Hospital Hangzhou China
3 shared publicationsRangxiao Zhuang
Department of Pharmaceutical Preparation, Hangzhou Xixi Hospital, Hangzhou 310023, Zhejiang Province, China
3 shared publicationsRuoyu He
Department of Pharmaceutical Preparation, Hangzhou Xixi Hospital, Hangzhou, China
3 shared publications- Shourong Liu
Hangzhou Xixi Hospital, Hangzhou, China
3 shared publications
Latest Publications
- 15 January 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 305, 118586
Broadening the horizon: The promise of PROTACs in non-malignant disorders
- 15 January 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 305, 118586
Broadening the horizon: The promise of PROTACs in non-malignant disorders
- Open Access
- 21 November 2025
- Published by Wiley in Archiv der Pharmazie
- Vol. 358 (11) , e70136
Identification of Novel β ‐Lactam Derivatives as Proteasome Inhibitors for Antitumor Therapy
A series of dipeptidic proteasome inhibitors with β ‐lactam as the C ‐terminus was designed and synthesized. Biochemical evaluations of their effects on chymotrypsin‐like (CT‐L) activity revealed that some of them had inhibitory activity against the proteasome, with IC 50 values in the micromolar range. Based on the enzymatic results, structure–activity relationships (SAR) were discussed in detail. Some potent compounds were further selected for antiproliferative assays toward multiple cancer cell lines, with compounds 66 and 78 demonstrating activity against RS4;11 cells and IC 50 values of less than 1 μM. Additionally, cellular mechanistic studies indicated that these effects were linked to their ability to inhibit proteasome signal pathways and to induce apoptosis in RS4;11 cells, as demonstrated by flow cytometry. Collectively, these results illustrate that compound 66 is a potent proteasome inhibitor with significant potential as an antitumor agent.
- 21 November 2025
- Published by Wiley in Archiv der Pharmazie
- Vol. 358 (11) , e70136
Open AccessIdentification of Novel β ‐Lactam Derivatives as Proteasome Inhibitors for Antitumor Therapy
A series of dipeptidic proteasome inhibitors with β ‐lactam as the C ‐terminus was designed and synthesized. Biochemical evaluations of their effects on chymotrypsin‐like (CT‐L) activity revealed that some of them had inhibitory activity against the proteasome, with IC 50 values in the micromolar range. Based on the enzymatic results, structure–activity relationships (SAR) were discussed in detail. Some potent compounds were further selected for antiproliferative assays toward multiple cancer cell lines, with compounds 66 and 78 demonstrating activity against RS4;11 cells and IC 50 values of less than 1 μM. Additionally, cellular mechanistic studies indicated that these effects were linked to their ability to inhibit proteasome signal pathways and to induce apoptosis in RS4;11 cells, as demonstrated by flow cytometry. Collectively, these results illustrate that compound 66 is a potent proteasome inhibitor with significant potential as an antitumor agent.
- Open Access
A “turn-on” fluorescence polyethyleneimine-based nanosensor chemosensor for sensing of l-lysine
- Open Access
- 1 January 2024
- Published by Wiley in Journal of Chemistry
- Vol. 2024 (1)
Efficient Removing of Pharmaceutical Contaminants of Commercial Carbamazepine by Natural Pyrite‐Induced Fenton Reaction in a Wide pH Range
Pharmaceutical contaminants are causing great attention for the public people, urgently requiring to be eliminated from the environment. Herein, commercial pharmaceutical carbamazepine was chosen as a model to be degraded by a heterogeneous Fenton system using natural pyrite as catalyst. The catalyst was characterized by X‐ray diffraction apparatus, high‐resolution transmission electron microscopy, and X‐ray photoelectron spectroscopy. The elements composition and chemical states of pyrite changed significantly after the Fenton reaction, which promoted the production of active species in the electron transfer process. The degradation efficiency of carbamazepine (2.5 mg/L) can reach 99.71% after 30 min with 0.3 g/L of pyrite and 5 mM of H2O2, respectively. The reaction system was suitable for a wide range of pH (3–9). The environmental adaptability examination of pyrite showed that humic acid (HA) had inhibitory effects on the degradation of carbamazepine. While the changes of degradation efficiency of carbamazepine were inconspicuous in the presence of and , indicating strong anti‐interference to environment common anions. Free‐radical capturers suggested that hydroxyl radical (∙OH), superoxide radical (), and singlet oxygen (1O2) participated in the degradation of carbamazepine. This research has offered a new strategy of “treating wastes with wastes” to use pyrite to remove emerging pollutants.
- 1 January 2024
- Published by Wiley in Journal of Chemistry
- Vol. 2024 (1)
Open AccessEfficient Removing of Pharmaceutical Contaminants of Commercial Carbamazepine by Natural Pyrite‐Induced Fenton Reaction in a Wide pH Range
Pharmaceutical contaminants are causing great attention for the public people, urgently requiring to be eliminated from the environment. Herein, commercial pharmaceutical carbamazepine was chosen as a model to be degraded by a heterogeneous Fenton system using natural pyrite as catalyst. The catalyst was characterized by X‐ray diffraction apparatus, high‐resolution transmission electron microscopy, and X‐ray photoelectron spectroscopy. The elements composition and chemical states of pyrite changed significantly after the Fenton reaction, which promoted the production of active species in the electron transfer process. The degradation efficiency of carbamazepine (2.5 mg/L) can reach 99.71% after 30 min with 0.3 g/L of pyrite and 5 mM of H2O2, respectively. The reaction system was suitable for a wide range of pH (3–9). The environmental adaptability examination of pyrite showed that humic acid (HA) had inhibitory effects on the degradation of carbamazepine. While the changes of degradation efficiency of carbamazepine were inconspicuous in the presence of and , indicating strong anti‐interference to environment common anions. Free‐radical capturers suggested that hydroxyl radical (∙OH), superoxide radical (), and singlet oxygen (1O2) participated in the degradation of carbamazepine. This research has offered a new strategy of “treating wastes with wastes” to use pyrite to remove emerging pollutants.
- 31 March 2023
- Published by Elsevier in Bioorganic Chemistry
- Vol. 135, 106507
Recent advances and future perspectives of noncompetitive proteasome inhibitors
- 31 March 2023
- Published by Elsevier in Bioorganic Chemistry
- Vol. 135, 106507
Recent advances and future perspectives of noncompetitive proteasome inhibitors
- Open Access
- 21 December 2022
- Published by Springer Nature in Research Square
Design, synthesis and biological evaluation of aminopyrimidine derivatives bearing dihydroquinoxalinone as novel EGFRL858R/T790M kinase inhibitors against non-small-cell lung cancer
The clinical responses to the EGFR kinase inhibitors in non-small cell lung cancer (NSCLC) patients are always followed by drug-resistance mutations, including the gatekeeper T790M mutation. Strategies targeting EGFRT790M are also limited by the toxicity due to the concurrent inhibition of wide-type (WT) EGFR. Here we employed splicing principle to design and synthesize a series of aminopyrimidine derivatives bearing dihydroquinoxalinone (8-15) as novel thirdgeneration inhibitors against double mutant L858R/T790M in EGFR. It’s worth noting that compound 10 presented remarkable inhibitory activity against EGFRL858R/T790M (IC50 = 15 ± 1.8 nM) and anti-proliferative effect against H1975 cells (IC50 = 166.43 ± 14.45 nM). Moreover, the obvious down-regulation effect of EGFR-mediated signaling pathways and the promotion of apoptosis in H1975 cells confirmed its potent efficacy. These results demonstrated that compound 10 deserves the further exploration.
- 21 December 2022
- Published by Springer Nature in Research Square
Open AccessDesign, synthesis and biological evaluation of aminopyrimidine derivatives bearing dihydroquinoxalinone as novel EGFRL858R/T790M kinase inhibitors against non-small-cell lung cancer
The clinical responses to the EGFR kinase inhibitors in non-small cell lung cancer (NSCLC) patients are always followed by drug-resistance mutations, including the gatekeeper T790M mutation. Strategies targeting EGFRT790M are also limited by the toxicity due to the concurrent inhibition of wide-type (WT) EGFR. Here we employed splicing principle to design and synthesize a series of aminopyrimidine derivatives bearing dihydroquinoxalinone (8-15) as novel thirdgeneration inhibitors against double mutant L858R/T790M in EGFR. It’s worth noting that compound 10 presented remarkable inhibitory activity against EGFRL858R/T790M (IC50 = 15 ± 1.8 nM) and anti-proliferative effect against H1975 cells (IC50 = 166.43 ± 14.45 nM). Moreover, the obvious down-regulation effect of EGFR-mediated signaling pathways and the promotion of apoptosis in H1975 cells confirmed its potent efficacy. These results demonstrated that compound 10 deserves the further exploration.
- Open Access
- 1 January 2021
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2021 (1)
Regulation of Mitochondrial Function by Natural Products for the Treatment of Metabolic Associated Fatty Liver Disease
Metabolic associated fatty liver disease (MAFLD) is a multifactorial systemic disorder that occurs in the absence of excessive alcohol consumption. The disease is characterized by fatty degeneration and fat accumulation in liver parenchymal cells, the incidence of which is increasing annually, particularly in younger adults. MAFLD is caused by genetic and metabolism related disorders, of which mitochondrial dysfunction is the major contributor. Natural products can relieve MAFLD through restoring mitochondrial function. In this article, we describe the relationship between mitochondria and MAFLD and discuss the beneficial effects of natural products as a future anti‐MAFLD strategy. Significance Statement. We herein propose that the development of mitochondrial regulators/nutrients from natural products can remedy mitochondrial dysfunction which represents an attractive strategy for the treatment of MAFLD. Furthermore, the mitochondrial regulation of natural products can provide new insight into the underlying mechanisms of action of natural products used for future MAFLD therapeutics.
- 1 January 2021
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2021 (1)
Open AccessRegulation of Mitochondrial Function by Natural Products for the Treatment of Metabolic Associated Fatty Liver Disease
Metabolic associated fatty liver disease (MAFLD) is a multifactorial systemic disorder that occurs in the absence of excessive alcohol consumption. The disease is characterized by fatty degeneration and fat accumulation in liver parenchymal cells, the incidence of which is increasing annually, particularly in younger adults. MAFLD is caused by genetic and metabolism related disorders, of which mitochondrial dysfunction is the major contributor. Natural products can relieve MAFLD through restoring mitochondrial function. In this article, we describe the relationship between mitochondria and MAFLD and discuss the beneficial effects of natural products as a future anti‐MAFLD strategy. Significance Statement. We herein propose that the development of mitochondrial regulators/nutrients from natural products can remedy mitochondrial dysfunction which represents an attractive strategy for the treatment of MAFLD. Furthermore, the mitochondrial regulation of natural products can provide new insight into the underlying mechanisms of action of natural products used for future MAFLD therapeutics.
- Open Access
- 1 October 2020
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 14, 4327-4342
Proteasome, a Promising Therapeutic Target for Multiple Diseases Beyond Cancer
Abstract : Proteasome is vital for intracellular protein homeostasis as it eliminates misfolded and damaged protein. Inhibition of proteasome has been validated as a powerful strategy for anti-cancer therapy, and several drugs have been approved for treatment of multiple myeloma. Recent studies indicate that proteasome has potent therapeutic effects on a variety of diseases besides cancer, including parasite infectious diseases, bacterial/fungal infections diseases, neurodegenerative diseases and autoimmune diseases. In this review, recent developments of proteasome inhibitors for various diseases and related structure activity relationships are going to be summarized.
- 1 October 2020
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 14, 4327-4342
Open AccessProteasome, a Promising Therapeutic Target for Multiple Diseases Beyond Cancer
Abstract : Proteasome is vital for intracellular protein homeostasis as it eliminates misfolded and damaged protein. Inhibition of proteasome has been validated as a powerful strategy for anti-cancer therapy, and several drugs have been approved for treatment of multiple myeloma. Recent studies indicate that proteasome has potent therapeutic effects on a variety of diseases besides cancer, including parasite infectious diseases, bacterial/fungal infections diseases, neurodegenerative diseases and autoimmune diseases. In this review, recent developments of proteasome inhibitors for various diseases and related structure activity relationships are going to be summarized.
- 24 July 2019
- Published by Wiley in Archiv der Pharmazie
- Vol. 352 (8) , e1900024
Design, synthesis, and biological evaluation of novel 3‐(thiophen‐2‐ylthio)pyridine derivatives as potential multitarget anticancer agents
A series of novel 3‐(thiophen‐2‐ylthio)pyridine derivatives as insulin‐like growth factor 1 receptor (IGF‐1R) inhibitors was designed and synthesized. IGF‐1R kinase inhibitory activities and cytotoxicities against HepG2 and WSU‐DLCL2 cell lines were tested. For all of these compounds, potent cancer cell proliferation inhibitory activities were observed, but not through the inhibition of IGR‐1R. Selected compounds were further screened against various kinases. Typical compound 22 (50% inhibitory concentration [IC50] values, HepG2: 2.98 ± 1.11 μM and WSU‐DLCL2: 4.34 ± 0.84 μM) exhibited good inhibitory activities against fibroblast growth factor receptor‐2 (FGFR2), FGFR3, epidermal growth factor receptor, Janus kinase, and RON (receptor originated from Nantes), with IC50 values ranging from 2.14 to 12.20 μM. Additionally, the cell‐cycle analysis showed that compound 22 could arrest HepG2 cells in the G1/G0 phase. Taken together, all the experiments confirmed that the compounds in this series were multitarget anticancer agents worth further optimizing.
- 24 July 2019
- Published by Wiley in Archiv der Pharmazie
- Vol. 352 (8) , e1900024
Design, synthesis, and biological evaluation of novel 3‐(thiophen‐2‐ylthio)pyridine derivatives as potential multitarget anticancer agents
A series of novel 3‐(thiophen‐2‐ylthio)pyridine derivatives as insulin‐like growth factor 1 receptor (IGF‐1R) inhibitors was designed and synthesized. IGF‐1R kinase inhibitory activities and cytotoxicities against HepG2 and WSU‐DLCL2 cell lines were tested. For all of these compounds, potent cancer cell proliferation inhibitory activities were observed, but not through the inhibition of IGR‐1R. Selected compounds were further screened against various kinases. Typical compound 22 (50% inhibitory concentration [IC50] values, HepG2: 2.98 ± 1.11 μM and WSU‐DLCL2: 4.34 ± 0.84 μM) exhibited good inhibitory activities against fibroblast growth factor receptor‐2 (FGFR2), FGFR3, epidermal growth factor receptor, Janus kinase, and RON (receptor originated from Nantes), with IC50 values ranging from 2.14 to 12.20 μM. Additionally, the cell‐cycle analysis showed that compound 22 could arrest HepG2 cells in the G1/G0 phase. Taken together, all the experiments confirmed that the compounds in this series were multitarget anticancer agents worth further optimizing.